Đang chuẩn bị liên kết để tải về tài liệu:
Metronomic chemotherapy with oral navelbine produces clinical benefit and low toxicity in metastatic breast cancer in K-Hospital

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

The metronomic concept emerged more than 20 year sago, however, a significant development in various solidtumors was noticed in the past 10 years. There are potentially several mechanisms of action against tumor cells including inhibition of angiogenesis. This study aims to assess the efficacy and the safety of ametronomic schedule of oral Vinorelbine (Navelbine) in treatment of metastatic breast cancer. |

TÀI LIỆU LIÊN QUAN

Head and neck cancer: Metronomic chemotherapy

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: Final results of the exploratory phase 2 Victor-5 study

Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma

SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2- negative advanced stage breast cancer - a multicenter, randomized phase III trial

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: A hellenic cooperative oncology group clinical translational study

Metronomic chemotherapy with oral navelbine produces clinical benefit and low toxicity in metastatic breast cancer in K-Hospital

A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic nonsmall cell lung cancer and malignant pleural mesothelioma: Rationale and study protocol

Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts

PRIMMO study protocol: A phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer